day) becomes more apparent. Importantly, loss of nocturnal dipping is associated with CKD progression.
C hronic kidney disease (CKD) is common, affecting 6% to 11% of the population globally, 1 and is strongly associated with incident CVD. 2 Hypertension is an independent risk factor for both CKD progression and CVD 3 and is a frequent finding in patients with CKD. Despite treatment with multiple antihypertensive agents, the majority of patients with CKD fail to reach target blood pressure (BP). 4 In healthy volunteers, BP shows a 24-hour (diurnal) variation with a nocturnal dip of ≈10% to 20% (commonly known as a dipping BP profile). 5, 6 Nondipping BP (often defined as a fall in nocturnal BP of <10%) 6 is associated with an increased risk of CVD, so BP dipping is thought to confer benefit. 7 A few studies have examined the 24-hour variation of BP in CKD. [8] [9] [10] They suggest that not only is nondipping a feature of CKD but also as glomerular filtration rate declines, reverse dipping (nighttime BP readings that are higher than those during the Recently, we showed that chronic selective ET A receptor antagonism-using the orally active drug sitaxentan-reduces BP, proteinuria, and more novel cardiovascular disease (CVD) risk factors including arterial stiffness, uric acid, and asymmetrical dimethylarginine in patients with proteinuric CKD, 18, 19 effects that are potentially renoprotective. Here, we present data from 3 studies: in the first, we examined the nocturnal dip in both ambulatory BP and arterial stiffness in patients with CKD and controls. In the second, we examined the 24-hour variation of plasma and urine ET-1 in patients with CKD and healthy volunteers. In the third, in a post hoc analysis of our earlier study with the selective ET A receptor antagonist, sitaxentan, we examined the effects of treatment on the 24-hour BP profile in clinical CKD. These studies were designed to address the overall hypothesis that the ET system contributes to increases in BP and arterial stiffness, and a loss of 24-hour variation in these important independent cardiovascular risk factors, in patients with CKD.
Methods

Methods are also available in the online-only Data Supplement
Case-Control Study: 24-Hour Variation in 24-Hour BP and 24-Hour Arterial Stiffness in CKD
This study compared 24-hour ambulatory BP and arterial stiffness in patients with CKD and matched controls. In brief, subjects were recruited from the renal outpatient clinic at the Royal Infirmary of Edinburgh and categorized into the 5 stages of CKD on the basis of the Kidney Disease Outcome Quality Initiative classification. 20 Agematched controls were recruited from the community. All subjects continued their normal medications during the study.
Subjects underwent monitoring with the TensioMed Arteriograph 24 ambulatory arterial stiffness pulse wave velocity (PWV) monitor (TensioMed Ltd, Hungary) for 24 hours. Measurements of BP and arterial stiffness were taken every 30 minutes from 0630 to 2130 and every hour from 2200 to 0600. At each time point, the arteriograph records aortic PWV, aortic systolic BP (SBP) and diastolic BP (DBP), brachial SBP and DBP, and heart rate. The arteriograph has been validated against an invasive measure of aortic PWV 21 and 2 commonly used noninvasive measurement devices, the Complior and SphygmoCor. 22, 23 Data presented are for brachial BP with day defined as 0630 to 1800 and night as 1830 to 0600. Subjects were excluded from the analysis if there were <50% of readings for both day and night BP and PWV.
Blood and urine samples were obtained from subjects after 12 hours fasting and before arteriograph monitoring. Creatinine clearance, as an estimate of glomerular filtration rate, was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation.
24
Observational Study: 24-Hour Variation in Plasma and Urinary ET-1 in CKD This study examined the 24-hour variation in plasma and urinary ET-1 in 15 subjects with CKD recruited from the renal outpatient clinic and from 15 volunteers recruited from the community. Paired blood and urine samples were taken at midday and midnight. ET-1 venous blood samples were collected in EDTA tubes. These were immediately centrifuged at 2500g for 20 minutes at 4°C. For urine ET-1, a sample of urine was collected into a plain container. Samples were stored at −80°C until analysis.
ET-1 was determined by ELISA (Biomedica Medizinprodukte GmbH). The mean recovery of ET-1 was >95% for both plasma and urine. The intra-assay and interassay variations were 4% and 6%, respectively. The cross-reactivity of the assay was 100% with ET-1 and ET-2, <5% for ET-3, and <1% with big ET-1. Fractional excretion of endothelin-1-1 was calculated by ([urine ET-1/plasma ET1×plasma creatinine/urine creatinine]×100)%.
Interventional Study: Effects of Selective ET A Receptor Antagonism on 24-Hour BP in CKD
The rationale and design for this study have been reported elsewhere. 18 In brief, in a randomized, double-blind, 3-way crossover study, 27 subjects on recommended renoprotective treatment received 6 weeks of placebo, sitaxentan 100 mg QD, and nifedipine LA 30 mg QD. Twenty-four-hour proteinuria, urine protein:creatinine ratio, 24-hour ambulatory BP, and PWV, as an index of arterial stiffness, were measured at baseline, week 3, and week 6 of each treatment period. Twenty-four-hour variation in BP was assessed at baseline and week 6 of each study period, with day defined as 0630 to 1800 and night as 1830 to 0600.
ET-1 venous blood samples were collected in EDTA tubes. These were immediately centrifuged at 2500g for 20 minutes at 4°C. For urine ET-1, a 20 mL aliquot of urine was collected into plain tubes with 2.5 mL of 50% acetic acid. Samples were stored at −80°C until analysis.
After extraction, 25 ET-1 was determined by radioimmunoassay. 26 The mean recovery of ET-1, from extraction to assay, was >90% for both plasma and urine. The intra-assay and interassay variations were 6.3% and 7.2%, respectively. The cross-reactivity of the antibody was 100% with ET-1, 7% for both ET-2 and ET-3, and 10% with big ET-1.
Statistical Analysis
Data were statistically analyzed using the GraphPad Prism, version 5. Descriptive data are given as mean±SD. Statistical analysis was performed on untransformed data. Data were compared using repeated measures 1-way ANOVA with Bonferroni correction for multiple comparisons. Correlation coefficients were calculated using the Pearson method. For study 3, the primary and secondary end point data were analyzed using a mixed model with repeated measures. Statistical significance was taken at the 5% level.
Results
Case-Control Study: 24-Hour Variation in 24-Hour BP and 24-Hour Arterial Stiffness in CKD
Twenty patients with varying degrees of CKD and 17 matched controls were recruited into this study. Of these, 5 patients with CKD and 2 controls were excluded from the analysis because they had <50% of readings for both day and night BP and PWV. For the remaining 15 patients with CKD, diagnoses were hypertensive nephrosclerosis (n=5, 33%), IgA nephropathy (n=5, 33%), unknown cause for their CKD (n=3, 20%), and reflux nephropathy (n=2, 13%). Baseline parameters are shown in Table 1 .
24-Hour Variation in SBP
Overall, 24-hour SBP did not differ between the groups: control versus CKD, 132±12 versus 136±12 mm Hg (P=NS). Similarly, day and night SBP were not different between the 2 groups ( Figure 1A ). However, whereas control subjects had a significant nocturnal dip in SBP of −3.2±4.8% (P=0.02), patients with CKD did not (for BP dip, controls versus CKD P=0.43; Figure 1A ).
24-Hour Variation in DBP
As for SBP, overall 24-hour DBP did not differ between groups: control versus CKD, 87±9 versus 86±8 mm Hg (P=NS), and similarly, day and night DBP did not differ between the 2 groups ( Figure 1B Figure 1B ).
24-Hour Variation in Arterial Stiffness
Twenty-four-hour aortic PWV was similar between control and CKD subjects: control versus CKD, 8.3±1.1 versus 8.2±0.9 m/s (P=NS). Similarly, day and night PWV did not differ between the 2 groups ( Figure 1C ). Whereas PWV fell at night in control subjects (−5.8±5.2%; P<0.01), it did not in those with CKD (for PWV dip, controls versus CKD P=0.17; Figure 1C ). Table 2 . Whereas in healthy volunteers plasma ET-1 fell from 4.8±1.4 at midday to 3.9±1.3 pg/mL at midnight (P=0.02), it increased from 4.8±1.5 to 5.1±1.5 pg/mL in patients with CKD (P<0.01; Figure 2A ). Midday plasma ET-1 did not differ between healthy volunteers and patients with CKD, whereas midnight concentrations were higher in CKD (P=0.02). Ten of 15 healthy volunteers showed a nocturnal fall in plasma ET-1, whereas a nocturnal rise was seen in 12 of the 15 CKD subjects ( Figure 2B ). There was no 24-hour variation in urinary ET-1 in either healthy volunteers or disease (fractional excretion of ET-1 at midday versus midnight: 2.12±1.23% versus 1.93±1.12% for healthy volunteers; 3.79±1.83% versus 3.74±1.30% for patients with CKD, P=NS for both; P<0.01 for both midday healthy volunteers versus midday patients with CKD and midnight healthy volunteers versus midnight ACE inhibitor 1 (7) 6 (40) ARB 1 (7) 2 (13) α-Blocker 0 4 (27) β-Blocker 1 ( 
Interventional Study: Effects of Selective ET A Receptor Antagonism on 24-Hour BP in CKD
Twenty-seven patients with CKD were recruited into this study, and all patients completed all 3 phases of the study, with each subject having >50% of readings for both day and nighttime BP on all 24-hour ambulatory monitors. Patient diagnoses were IgA nephropathy (n=14, 52%), focal segmental glomerulosclerosis (n=6, 22%), membranous nephropathy (n=3, 11%), hypertensive nephrosclerosis (n=2, 7%), reflux nephropathy (n=1, 4%), and unknown cause of CKD (n=1, 4%). Subject baseline parameters are shown in Table 3 . For all subjects, baseline parameters did not differ between the 3 study phases. Individual subject characterization is provided in Table S1 in the online-only Data Supplement.
Described elsewhere, 18 after 6-week dosing, there were no significant differences between sitaxentan and nifedipine in the reductions from baseline in 24-hour BP parameters. Despite this, sitaxentan reduced proteinuria to a significantly greater extent than nifedipine. PWV fell to a similar degree with nifedipine and sitaxentan. Placebo did not affect proteinuria, BP, or PWV (Table 4 for summary data). There was no evidence of a period effect.
24-Hour Variation in SBP
At baseline, for all 3 phases of the study, there was a nocturnal dip in SBP that did not differ between treatment arms (Table  S2 ; Figure S1 ): placebo −5.2±5.3%, sitaxentan −5.4±4.6%, nifedipine −5.7±5.0% (ANOVA P=NS). After 6-week treatment, this nocturnal dip persisted in the 3 treatment arms: placebo −4.8±7.3%, sitaxentan −8.8±5.9%, nifedipine −4.6±4.9%. Between groups ANOVA, P=0.002; for sitaxentan versus both placebo and nifedipine, P<0.01. However, whereas placebo and nifedipine did not affect the degree of nocturnal dip in SBP between baseline and week 6, the dip was greater after treatment with sitaxentan (Figure 3) , baseline versus week 6: placebo −6.8±7.5 versus −6.5±9.8 mm Hg, P=NS; sitaxentan −7.0±6.2 versus −11.0±7.8 mm Hg, P<0.05; nifedipine −7.5±6.9 versus −6.0±6.4 mm Hg, P=NS.
24-Hour Variation in DBP
As for SBP, there was a nocturnal dip in DBP at baseline that did not differ between treatment arms (Table S2; Figure  S2 ): placebo −7.6±6.4%, sitaxentan −7.4±4.2%, nifedipine −8.3±5.1%, (ANOVA P=NS). After 6-week treatment, this nocturnal dip in DBP persisted in the 3 treatment arms: placebo −7.2±5.7%, sitaxentan −10.4±5.9%, nifedipine −7.0±5.1%. Between groups ANOVA, P=0.007; for sitaxentan versus both placebo and nifedipine, P<0.05. However, similar to SBP, whereas placebo and nifedipine did not change the degree of nocturnal dip in DBP between baseline and week 6, sitaxentan increased the dip (Figure 3) , baseline versus week 6: placebo −6.3±5.6 versus −6.0±4.9 mm Hg, P=NS; sitaxentan −6.0±3.6 versus −8.3±5.1 mm Hg, P<0.05; nifedipine −6.9±4.4 versus −5.7±4.1 mm Hg, P=NS.
Twenty-Four-Hour Variation in Pulse Pressure
There was no significant nocturnal dip in pulse pressure (PP) at baseline in the 3 phases of the study (Table S2 ; Figure S3 ). Although this remained the case after 6 weeks of placebo and nifedipine, treatment with sitaxentan was associated with the development of a nocturnal dip in PP, day versus night: 46±7 versus 43±7 mm Hg, P<0.01. Between groups ANOVA, P=0.005; sitaxentan versus placebo, P<0.01.
Plasma ET-1 concentrations were similar at baseline in all 3 phases of the study and were not affected by any of the interventions (Table 4) . Baseline urine ET-1 levels were also similar in all 3 phases of the study. Whereas placebo and nifedipine had no effect on urine ET-1, sitaxentan reduced this by ≈20% (Table 4) .
Discussion
We have shown, for the first time, that patients with CKD lack the diurnal variation in arterial stiffness seen in matched subjects without CKD. We have also confirmed previous data showing that there is a loss in nocturnal BP dipping in this cohort. With regard to the ET system, we report the novel observation of a 24-hour variation in plasma ET-1 with a nighttime rise in patients with CKD compared with a fall in healthy volunteers. Finally, we have shown that medium-term dosing with a selective ET A receptor antagonist produces a greater fall in nocturnal BP compared with an alternative BP-lowering method with a similar overall 24-hour antihypertensive profile.
Ambulatory BP monitoring is a useful clinical tool and a stronger predictor than clinic BP of CVD morbidity and 27 A recent study in patients with varying degrees of CKD showed that ambulatory BP monitoring and, in particular, nighttime BP measurement allowed better prediction of renal and CVD risk than office BP, which did not predict either outcome. 28 Furthermore, those who were nondippers or reverse dippers had a greater risk of both end points. The mean glomerular filtration rate of those patients (43 mL/min) was similar to that of ours. Interestingly, a recent study from Japan showed that nighttime BP better predicts incident CKD in the general population than does daytime BP. 29 Arterial stiffness is an independent predictor of all-cause and CVD mortality in patients with end-stage renal disease. 12 Moreover, a therapeutic trial in patients with end-stage renal disease 30 has shown that after long-term BP reduction, cardiovascular survival was observed mainly in those patients showing adequate reduction of both BP and PWV. Patients with appropriate BP reduction but who maintained an elevated PWV did not survive. Thus, arterial stiffness is a potentially valuable target for treatment in CKD. It has been suggested that arterial stiffening may be protective, reducing the transmission of pulsatility to the microcirculation, particularly in organs with low resistances to flow such as the kidney. 31 However, this was recently discounted in a study looking at renal vascular damage in patients with hypertension. 32 Ours are the first data describing the 24-hour profile of arterial stiffness in CKD.
Although the control subjects in study 1 had good SBP and DBP control, they were in their sixth decade with a high body mass index and some had hypertension. This may partly explain why the 24-hour BP variation (≈3% nocturnal dip in SBP, ≈6% dip in DBP) was less impressive than expected in a healthy population (≈10%-20%). Furthermore, PWV (≈8 m/s for both CKD and non-CKD cohort) was higher 33 than one study in subjects with a similar degree of renal impairment and lower 34 than another. The differences may relate to the methods of arterial stiffness measurement and differences in the presence of overt and subclinical CVD. The lack of nocturnal dip in arterial stiffness in CKD may be, at least partly, a consequence of the lack of BP dip because this is the major factor governing PWV. 35 In study 2, we have shown that the nocturnal dip in plasma ET-1 in healthy volunteers is reversed in patients with CKD. A circadian rhythm of plasma ET-1, in both healthy volunteers 36 and patients with CKD, 37 has been previously described, but it is likely that this will vary between tissues and diseases. The explanation for this 24-hour variation in ET system activation is unclear, but an elegant study has shown that the circadian protein period 1 regulates ET-1 mRNA and protein in the kidney, and this contributes to the regulation of renal sodium transport and so BP. 38 In that study, the authors observed changes in renal ET-1 production, which may also be assessed using urinary ET-1. 39 In our study, we saw no day-night variation in urinary ET-1, but this may be a reflection of sample size and timing of sample collection. Certainly, the causes and consequences of this 24-hour variation in the ET system in CKD should be a focus of further research.
The results of study 3 show that 6-week treatment with a selective ET A receptor antagonist increased the nocturnal dip in both SBP and DBP in patients with CKD. Interestingly, these subjects did display dipping of both SBP (≈5%) and DBP (≈7%) at baseline. This degree of 24-hour BP variation was greater than that seen in the CKD subjects in study 1 (≈2% dip in SBP; ≈3% dip in DBP). Explanations for this may include a healthier cohort from a cardiovascular perspective in study 3 and differences between the 2 groups in the timing of their antihypertensive medications. Four of 15 subjects in study 1 were taking ≥1 of their antihypertensive agents in the evening, whereas this was the case in 14 of 27 subjects in study 3. Nighttime dosing of antihypertensive medications (chronotherapy) is a well-recognized treatment strategy. In a study where untreated hypertensive subjects were randomized to ramipril given either in the morning or at night, 40 those receiving the drug at night had greater nocturnal BP dipping. The same authors have subsequently shown that bedtime dosing of ≥1 antihypertensive reduces CVD risk in those with CKD. 41 In study here, exclusion of the 4 subjects taking antihypertensive medication at night made no effect on the analyses for SBP and DBP but did accentuate the fall in PWV closer to that seen in healthy volunteers (from −2.4±8.0 to −4.3±5.6%; −5.8±5.2% in healthy volunteers).
The findings of our interventional study are in line with a recently published study that assessed the efficacy of a combined inhibitor of the endothelin-converting enzyme and neutral endopeptidase in patients with type 2 diabetes mellitus. 42 Interestingly, the effect of inhibitor on BP was also significantly higher at night and was achieved on top of a full-dose losartan plus ≥2 additional antihypertensive drugs in most patients. Taking these data together, the results suggest that ET-1 may be a key mediator in the 24-hour control of BP.
There are several possible explanations why the ET A antagonist sitaxentan improved BP dipping. First, the results of study 2 suggest nocturnal upregulation of the ET system in CKD. Thus, given a suitable pharmacokinetic profile, an antagonist may be more effective at night; and sitaxentan has a plasma half-life of ≈10 hours, allowing once a day dosing. 43 Second, the effects of an ET A receptor antagonist relate to the degree of renin-angiotensin system blockade. 44 In this study, 8 of 27 subjects were taking either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker at night, and this may have potentiated the effects of the ET A antagonist. Finally, a nondipping BP has been linked to salt retention with diuretics 45 and salt restriction 46 restoring a dipping phenotype. Treatment with a selective ET A receptor antagonist may allow an unblocked ET B receptor to promote natriuresis and diuresis, 16 allowing recovery of a dipping BP phenotype. Finally, sitaxentan allowed the development of a nighttime dip in PP. A higher 24-hour ambulatory PP, along with a loss of nocturnal BP dip, has been shown to be independent predictors of nephropathy progression in patients with type 2 diabetes mellitus. 47 Furthermore, a high PP is associated with brain 48 and kidney 49 damage. Arterial stiffness is a major determinant of PP, and it may be that the beneficial effects of sitaxentan on PWV partly explain the effects on PP. Unfortunately, we were unable to assess ambulatory PWV in this study, and so it remains unclear whether the beneficial effects of ET A antagonism on PWV show a diurnal variation.
Limitations
Although adequately powered, the studies described here were reasonably small and included only white subjects. Thus, extrapolation of the data must be done with caution. In the interventional study, sitaxentan dosing was not associated with any more adverse events than placebo. Importantly, we observed no weight gain, clinically significant edema, fall in hemoglobin, or hematocrit. Fluid retention has been observed in several trials with ET receptor antagonists, although its mechanism remains unclear. ET-1 acts in the renal tubule via the ET B receptor to promote natriuresis and diuresis. Thus, edema could be aggravated by mixed ET A/B antagonists, and its absence in the current study may be explained by the selective ET A blocking nature of our drug. In addition, the careful selection of our subjects, excluding those with clinically apparent cardiovascular disease and overt heart failure (and so a propensity to fluid overload), may also help.
Perspectives
Importantly, the current data suggest that a selective ET A blocking approach provides BP control alongside a decrease in nondipping status, both of which have been shown to provide a significant reduction in cardiovascular morbidity and mortality. Hermida et al 50 showed that in patients with hypertension a 17% reduction in cardiovascular risk for each 5-mm Hg decrease in asleep SBP, an effect similar to our own. Furthermore, recent data suggest potential interactions between genetic and environmental factors-relating to the ET system-to affect cardiovascular disease, in particular 24-hour BP variability. 51 Larger studies using a selective ET A blocking strategy are needed to confirm these important findings in a group of patients at high cardiovascular risk. Main study data at baseline and week 6 of each study period. Values are given as predosing baseline±SEM. BP indicates blood pressure; cAIx, central augmentation index; CKD, chronic kidney disease; ET-1, endothelin-1; ET A , endothelin receptor type A; MAP, mean arterial pressure; PCR, protein:creatinine ratio; and PWV, pulse wave velocity. *P<0.01, †P=0.01, ‡P<0.05 for week 6 vs baseline. 
Addendum
Sitaxentan has been voluntarily withdrawn by Pfizer, Ltd because of unacceptable side effects. However, the findings in this article are likely to be representative of the effects of the class of selective endothelin A receptor antagonists. What Is New?
Sources of Funding
• We have shown, for the first time, that patients with chronic kidney disease (CKD) lack the 24-hour variation in arterial stiffness seen in matched subjects without CKD. Alongside this, we have confirmed the results of previous studies showing that there is a loss in nocturnal blood pressure (BP) dipping in this cohort. With regard to the endothelin system, we report the novel observation of a 24-hour variation in plasma endothelin-1 with a nighttime rise in those with CKD compared with a 24-hour fall seen in healthy volunteers. Finally, we have shown that medium-term dosing with a selective endothelin receptor type A receptor antagonist produces a greater fall in nocturnal BP compared with an alternative BPlowering method with a similar overall 24-hour antihypertensive profile.
What Is Relevant?
• CKD is associated with a significant risk of cardiovascular disease that is contributed to by hypertension and a nondipping BP profile. Despite current therapies, many patients with CKD do not meet target BP. Newer agents that not only reduce BP but also improve nocturnal BP dipping, on top of standard therapies, may confer long-term cardiovascular benefits.
Supplemental methods
All 3 studies were carried out with the approval of the local research ethics committee and the written informed consent of each subject. The investigations conformed to the principles outlined in the Declaration of Helsinki.
Study 1 (case control study) Power calculation
This study was powered on the basis of preliminary data using the TensioMed Arteriograph 24 for arterial stiffness (pulse wave velocity, PWV) measurements. In young healthy individuals we have previously observed a difference in PWV between asleep and awake of 0.78m/s. A sample size of 9 would have a 90% power to detect a difference in means of PWV of 0.78m/s between asleep and awake using a standard deviation of 0.50m/s using a repeated measures ANOVA with p < 0.05.
There are no previous data relating to the 24h variation in arterial stiffness in patients with CKD. However, our own group has previously found differences of 0.80m/s in daytime PWV between stage 3 CKD patients and age matched controls. 1 A sample size of 15 in each group would have 90% power to detect a difference in means of PWV of 0.80m/s using a standard deviation of 1.00m/s using a repeated measures ANOVA with p < 0.05.
Inclusion & exclusion criteria
Inclusion criteria for both groups were: male or female, age 18 -79 years with a clinic BP <160/100mmHg (whether or not on antihypertensive medication). Patients with diabetes mellitus and a history of CVD were excluded.
Study 2 (observational study)
Power calculation
We had no previous data of our own with which to power this study and so this was based on a published study that looked at the 24h variation in plasma ET-1 in 9 healthy subjects. 2 In this study the authors found a circadian variation in plasma ET-1 with a nadir value of 0.61 ± 0.24pg/ml at 1600 hours and a peak of 0.84 ± 0.24pg/ml at 0800. In our study we examined 15 patients with CKD, in whom the ET system is known to be upregulated, and found a 24h variation in plasma ET-1 (but not urine ET-1) with a mean value of 4.8 ± 1.5pg/ml at midday rising to 5.1 ± 1.5pg/ml at midnight (p < 0.01).
Study 3 (interventional study)
The results of this study were a post hoc analysis with the original study powered for changes in blood pressure and proteinuria. 3 However, given the 24h changes in the components of blood pressure were statistically significant the study was adequately powered to detect these. 
